Evidence map›Paper›PMID 42367725›Full record

ArticleDrugs in context2026

Primary Sjögren's syndrome-associated interstitial lung disease: a case report with favourable response to tocilizumab.

Negar Naseri, Nadia Jalili, Farzad Rafiei, Saina Sadeghipour, Hamidreza Soltani

Abstract readCase Reports
In one paragraph

Article in Drugs in context, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Negar NaseriStudent Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Nadia JaliliStudent Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Farzad RafieiStudent Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Saina SadeghipourStudent Research Committee, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Hamidreza SoltaniDepartment of Rheumatology, School of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Severe pulmonary involvement in primary Sjögren's syndrome presents a therapeutic challenge, particularly when conventional immunosuppression is insufficient. We report on the case of a 50-year-old woman with interstitial lung disease and profound gas exchange impairment (DLCO 17%). Despite initial treatment with azathioprine, clinical response was inadequate. Early escalation to tocilizumab was followed by marked clinical and radiological improvement. This case highlights the potential importance of timely biologic intervention in severe disease and suggests that advanced functional impairment may still be reversible. Limitations include a single-case design and concomitant therapy.

Indexed as

autoimmune diseasescytokine inhibitorsinterstitial lung diseaseprimary Sjögren’s syndrometocilizumab

Identifiers

PMID42367725
PMCPMC13299342

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.